Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Freiburg Im Breisgau – page 28

529 clinical trials in Freiburg Im Breisgau, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Freiburg Im Breisgau at a glance
529
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

529 trials in Freiburg Im Breisgau

Open in trial search

Interstitial lung disease+1

Not recruiting

Study to Test if Nerandomilast (BI 1015550) Helps Patients with Interstitial Lung Disease Related to Rheumatic Diseases

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
  • Sponsor:Boehringer Ingelheim Espana S.A.

Oesophageal adenocarcinoma

Not recruiting

Study on ABBV-400, Fluorouracil, Leucovorin, and Budigalimab for Advanced or Metastatic Stomach and Esophageal Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cholangitis sclerosing

Not recruiting

Study on the Safety and Tolerability of Norucholic Acid Tablets for Patients with Primary Sclerosing Cholangitis (PSC)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Norucholic Acid
  • Sponsor:Dr. Falk Pharma GmbH

Generalised tonic-clonic seizure+1

Not recruiting

Study on PRAX-628 for Adults with Focal Onset or Generalized Tonic-Clonic Seizures

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prax-628
  • Sponsor:Praxis Precision Medicines Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Uveitis+1

Not recruiting

Study on the Effects of Brepocitinib and Prednisone for Adults with Active Non-Infectious Uveitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Priovant Therapeutics Inc.

Study on Higher Doses of Nusinersen for Patients with Spinal Muscular Atrophy Who Previously Participated in a Nusinersen Study

Not recruiting
InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Nusinersen
  • Sponsor:Biogen Idec Research Limited

Plasma cell myeloma refractory

Not recruiting

Study Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Kite Pharma Inc.

Giant cell arteritis

Not recruiting

Study of secukinumab and prednisone combination therapy for patients with giant cell arteritis (GCA): Evaluation of treatment effectiveness and safety

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Non-small cell lung cancer

Not recruiting

Study Comparing Datopotamab Deruxtecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.

Anal cancer stage II+1

Not recruiting

Study on Durvalumab with Radiochemotherapy for Patients with Locally-Advanced Anal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Goethe University Frankfurt

Adverse drug reaction+1

Not recruiting

Study on Methoxsalen for Treating Immune-Related Side Effects in Patients After Immunotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Methoxsalen
  • Sponsor:Medical Center - University Of Freiburg

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Freiburg Im Breisgau

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer, non-small cell lung cancer, and colon cancer treatments. Studies evaluating new therapeutic approaches for both early-stage and advanced cancers.

  • Breast Cancer Therapy Optimization
  • Advanced Lung Cancer Treatments
  • Gastrointestinal Cancer Research

Emphasis on targeted therapies and combination treatments to improve patient outcomes.

02 Autoimmune Conditions

Research into treatments for psoriatic arthritis, rheumatoid arthritis, and Sjögren's disease. Studies evaluating novel biologics and targeted therapies.

  • Inflammatory Arthritis Management
  • Autoimmune Disease Therapeutics
  • Novel Treatment Approaches

Focus on improving disease control and quality of life for patients with chronic autoimmune conditions.

03 Rare Diseases

Clinical investigations of treatments for spinal muscular atrophy, sickle cell disease, and primary sclerosing cholangitis. Studies aimed at developing innovative therapies.

  • Genetic Disease Treatments
  • Blood Disorders
  • Pediatric Rare Diseases

Dedicated to finding breakthrough treatments for challenging rare conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.